Across TCGA pan-cancer cohorts, OPALIN Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OPALIN data layer compared with 17 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher OPALIN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OPALIN expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.
CESC, SKCM, and SARC are the cancer types where OPALIN Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.